Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study
Authors:
Open Access
- 1 March 1991
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (3) , 420-423
Abstract
Twenty five hormone manipulated patients with prostate cancer and metastatic bone disease, treated at least 6/12 previously by hormone manipulation, were given intravenous infusions of Disodium Pamidronate (APD) over a 6 month period. Patients received 30 mg weekly for 4 weeks then twice monthly for 5 months. No other treatment was administered during study. Eleven of 17 patients with pain at the start of the study were pain free at the end. Fasting morning calcium excretion and serum osteocalcin fell significantly with Pamidronate (P less than 0.0001) and urine hydroxyproline was lowered in 13/20 evaluable patients at 6 months. Alkaline phosphatase fell in a proportion of patients and five of 17 patients with previously progressive bone scans stabilised (4) or regressed (1) on treatment. Rising acid phosphatase levels were also lowered in five patients. It is concluded that Pamidronate may be effective in palliating bone pain in some patients and has a stabilising influence on abnormally high bone turnover in metastatic prostate cancer. Further controlled studies of the compound are now warranted.Keywords
This publication has 12 references indexed in Scilit:
- PAMIDRONATE TO REDUCE BONE PAIN IN NORMOCALCAEMIC PATIENT WITH DISSEMINATED PROSTATIC CARCINOMAThe Lancet, 1989
- Bisphosphonates and bone metastasesBritish Journal of Cancer, 1988
- Management of pain and other symptoms of advanced prostatic cancer.1988
- Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ, 1988
- REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENTThe Lancet, 1987
- Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.1987
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBritish Journal of Urology, 1985
- COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIAThe Lancet, 1983
- Mechanisms of bone destruction in the development of skeletal metastasesNature, 1976
- Metastases in carcinoma.Analysis of 1000 autopsied casesCancer, 1950